three-dimensional-survival assays, and/or to use more sophisticated imaging strategies, in order to uncover more accurate prognostic markers and improved therapies. the international conference on invasion and Metastasis at the Max Delbrück center for Molecular Medicine provided an intriguing outlook on these pressing issues.
Introduction
Mortality in cancer patients is often caused by tumour recurrence or metastasis, rather than by the primary tumour. in order to understand cancer, it is crucial to elucidate how cells invade and survive in new environments, a process known as metastasis (Fig 1) . Despite years of research, few proteins have been confirmed experimentally to induce metastasis. Hence, we need to improve screening technologies by linking them to migration, invasion and Most tumours are epithelial in origin but show mesenchymal traits; therefore, the issue of how cells lose epithelial characteristics-the so-called EMt-has been the focus of much attention in recent years. this process was initially recognized in developing embryos, when cells in epithelia lose cell-cell contacts, acquire mesenchymal gene expression and finally migrate into new locations (Fig 1; thiery, 2002) . there is a large amount of evidence suggesting that similar molecules regulate cell fate during both normal development and tumorigenesis. in Berlin, it became evident that some of these molecules have been identified, although there is still much to discover about the complexity of tumour progression.
r. Weinberg (cambridge, Ma, uSa) gave the opening lecture, which was situated in the beautiful Berlin-Brandenburg academy of Sciences. He elaborated on the significant implications of the self-renewal ability of cancer cells for metastasis: stem cells are competent to initiate metastasis, whereas progenitor cells are not. indeed, epithelial cells might be 'educated' to become metastatic by specific factors such as ccL5. this chemokine is derived from mesenchymal stem cells, which are recruited to the tumourassociated stroma. When ccL5 is ectopically expressed in carcinoma cells, they acquire elevated metastatic potential without the presence of nearby mesenchymal stem cells (Karnoub et al, 2007) . Few signalling factors can elicit an EMt programme in cancer cells on their own and, instead, seem to act in various combinations. they seem to induce the expression of transcription factors that can programme an EMt-such as FOXc2, twist and Snail-in carcinoma cells. in addition, the expression of EMt-inducing transcription factors such as twist and Snail, as well as tgF-β1 treatment, can induce the expression of stem-cell traits in both normal and neoplastic epithelial cells (Mani et al, 2008) , explaining the profound similarities between embryonic-type stemness signatures and the expression profiles of de-differentiated human tumours. this begs the question of whether all tumorigenic cells are the product of an EMt-like programme to generate progeny akin to stem cells. Max Delbrück Center for Molecular Medicine, Berlin, Germany reviews me e t i n g rep or t t. Brabletz (Freiburg, germany) examined malignant progression at the invasive front of colorectal cancers, where there is aberrant expression of nuclear β-catenin and the homeobox transcription factor zEB1. among zEB1 transcriptional targets, many are poor prognosis markers; for example, laminin-α3 and laminin-β3. zEB1 also represses the expression of the microrNas mir-141 and mir200c-which promote epithelial differentiation in certain cells such as MDa-MB231-thereby promoting EMt (Burk et al, 2008) . importantly, both microrNas are downregulated in undifferentiated breast tumours. congruously, the targets of the microrNas are zEB1 itself and tgF-β2, leading to a positive feed-forward loop that reinforces EMt in invasive tumour cells. a. Ben-ze'ev (rehovot, israel) continued this theme by reminding us of the importance of Wnt-β-catenin signalling for cell-cell adhesion in metastasis. Even in cell culture, the intracellular distribution of the β-catenin/ E-cadherin system is as plastic as that within colon tumours. By increasing the density of cultured cells, β-catenin signalling is inhibited and the molecule is sequestered in cell-cell junctions. conversely, a sparse culture mirrors an invasive cellular system showing EgFr/MapK activation, in which high nuclear levels of β-catenin lead to the activation of Slug transcription, which is a target of β-catenin/tcF in colon cancer cells. Ben-ze'ev also presented L1-caM as an important target of β-catenin/tcF. L1-caM confers sustained ErK activation, allowing the cells to grow under low serum conditions, and ultimately is able to promote the metastasis of colon cancer cells to the liver (gavert et al, 2007) . this membrane glycoprotein is also the focus of p. altevogt (Heidelberg, germany). He showed that specific mutation of L1-caM, or neutralizing L1-caM antibodies, abolished ErK activation and thereby the induction of target genes such as β3-integrin and cathepsin-B (gast et al, 2008) . L1-caM is also thought to be a stem-cell marker in specific tissues such as the colon, as suggested by r. Fodde (rotterdam, the Netherlands) and Ben-ze'ev.
the identification of tumour-initiating cells in apc-mutant mammary and intestinal tumours is central to the work of Fodde. although the model predicts that each tumour cell should be identifiable by nuclear β-catenin accumulation, in mammary and intestinal tumours this is observed only for a minority of cells primarily distributed along the invasive front of the tumour. this is referred to as the 'β-catenin paradox' (Fodde & Brabletz, 2007) . Fodde reported the generation of a novel mouse model, Apc1572T, which results in intermediate levels of Wnt-β-catenin signalling activation when compared with other Apc mutations that are known to predispose to intestinal cancer. Notably, Apc +/1572t mice have no increased predisposition to intestinal cancer but develop mammary adenocarcinomas and subsequent metastases. the histology of these tumours is highly heterogeneous and presents luminal, myoepithelial and squamous lineages. Sorting of Apc1572t tumours for Lin -/cD29 hi / cD24 + cells results in the isolation of a relatively small subpopulation that is characterized by intracellular β-catenin accumulation and tumour-initiating ability. this population recapitulates tumorigenesis when transplanted in NOD-SciD animals at low multiplicities. Expression profiling of the normal and cancerassociated Lin -/cD29 hi /cD24 + stem cells revealed a marked similarity between the two populations, but also a distinct group of differentially expressed genes. Similarly, the laboratory of z. Werb (San Francisco, ca, uSa) is interested in the potential of breast tumours to acquire the ability to disseminate and metastasize, which correlates with oestrogen receptor levels and differentiation status of the tumour. She showed that the conditional loss of the zinc-finger transcription factor gata-3 in mice triggers an expansion of a stem-cell-like population during the early stages of malignant progression in luminal breast tumours (Kouros-Mehr et al, 2008) . therefore, in early lesions, loss of gata-3 alone is insufficient for malignant conversion but is required to maintain a tumour stem cell-like population (cD24 + /cD29 + ) that is increased at the expense of other lineages. Both of these findings highlight the need to characterize the precise stem-cell compartments, as the tumours show immense plasticity.
S. Hipp (Munich, germany) is interested in how the transcriptional repressor Snail-which controls EMt through the invasion suppressor E-cadherin-is regulated. to identify the elusive pathways that control Snail1 expression, reverse-phase protein microarrays on formalin fixed and paraffin embedded endometrial and ovarian tumours were used (Hipp et al, 2008) . By using this approach, Hipp suggested that EgF might lead to Snail1 protein stabilization. in agreement with the array data, patient survival studies indicate that Snail upregulation and high levels of MapK correlate with lower overall survival in human ovarian cancers. High Snail1 expression in the vicinity of tumours is consistent with the idea that it has a pro-EMt function in supporting caFs, as put forward by a. garcía de Herreros (Barcelona, Spain). He suggested that Snail1 prevents the processing of Zeb2 messenger rNa at a zinc-finger E-box binding homeobox 1 reviews me e t ing rep or t 5' untranslated region-located intron that contains an internal ribosome entry site, so that splicing modulates the translation of Zeb2. this mechanism, which leads to the initial downregulation and translational control of zeb1/2, is required for sustained E-cadherin repression (Beltran et al, 2008) . this highlights the importance of certain factors such as E-cadherin and the Wnt pathway for the regulation of EMt under physiological and pathological conditions. Whether every factor that facilitates an EMt-like programme is also competent to drive stemness and metastasis remains to be clarified.
to answer this question, accurate model systems are needed that show heterogeneity and plasticity within the tumour entity, similar to human tumours.
Screens for genes
although the past decade has seen the identification of specific genes that are important for invasion and metastasis, the complex multi-step nature of the process (Fig 1) suggests that a vast array of genes are likely to regulate it. Building a complete catalogue of metastasis genes therefore remains one of the main goals of the field; the Berlin meeting illustrated the breadth of approaches being used to tackle this issue. L. chin (Boston, Ma, uSa) outlined the efforts of her laboratory to identify cancer-relevant genes by using comparative oncogenomic approaches. comparing non-metastatic parental cells with metastatic clones using array comparative genomic hybridization (cgH) allowed the chin laboratory to identify NEDD9-which is located at 6q24-25, a region amplified in 35% of metastatic melanomas, as well as in tumours from other tissues (Kim et al, 2006) -as a driver of metastasis. NEDD9 associates with and activates FaK, leading to the formation of dynamic focal contacts and to the activation of rac through the FaK-crk-DOcK180 complex, thereby promoting invasion. the chin laboratory is now taking the mouse melanoma work further by using integrated genome comparison, which is a combination of array cgH and microarrays. this methodology, which correlates genomic alterations with transcript levels, has yielded far more informative answers than either method alone, and has produced a 'metastatic determinant signature', which comprises many cell-cycle and DNa-repair genes.
in an elegant and related approach, y. Kang (princeton, NJ, uSa) revisited some published microarray data from clinical tumour samples by transforming the differential microarray geneexpression profiles for the prediction of recurrent genomic alterations. the resultant 'gene-expression neighbourhood map' from three studies on metastatic breast cancer samples identified regions strongly correlated with poor prognosis. the analysis of these genes is ongoing and should yield some interesting candidates. in discussing these findings, chin pointed out that, although we have many markers of metastatic potential, the genes that are really driving this process are far from clear. Much functional work remains to be done and phenotype-based rNa interference screens look set to gain increasing importance. Several interesting screening approaches were highlighted, including rNa interference screens for cell-cell adhesion regulators by D. arlt (Heidelberg, germany) or cell migration by S. Naffar-abu-amara, from the geiger laboratory (rehovot, israel). these talks illustrated the power of genomics in identifying genes associated with tumour progression, and the growing importance of functional screens in filtering the genomic information in the hope of yielding the drug targets and diagnostic markers of the future.
It's alive! Live imaging of metastasis
For all the contributions of in vitro studies to our understanding of metastasis, intravital imaging techniques are revolutionizing our view of the process (Sahai, 2007) . Several talks illustrated these powerful approaches (Fig 2) . the r. Klemke group (La Jolla, ca, uSa) has developed a zebrafish xenograft system, which they use to study blood-vessel remodelling by injected MDa-435 melanoma cells. MDa cells are able to form tumours, but only enter the vasculature when they express both VEgF and rhoc (Fig 2a) . VEgF is required to induce angiogenesis and rhoc promotes the switch to an amoeboid form of migration, which allows the tumour cells to invade the 'leaky' new vessels (Stoletov & Klemke, 2008) . the potential of this system is impressive, as both the zebrafish host and the tumour cells can be manipulated to study various aspects of the metastatic process. in addition to rho expression, the switch to amoeboid migration can be elicited by inhibition of MMps, which allow tumour cells grown in a three-dimensional collagen meshwork to migrate through the matrix without degrading it by adopting a more fluid morphology (Wolf et al, 2007) . Following on from their initial work, the p. Friedl laboratory (Nijmegen, the Netherlands) visualized the foci of matrix degradation by using a fluorescent reporter for collagen degradation. these foci are present behind the leading edge of the leader cells, where the initial invasion occurs, and also as lateral spikes in the following cells, enlarging the burrow created by the leaders. could these structures be the three-dimensional equivalents of the invadopodia, actin and MMp-rich protrusions that have been observed in two-dimensional tissue culture? r. Buccione (S. Maria imbaro, italy) showed that invadopodia are also rich in cholesterol and that cholesterol homeostasis is required for matrix digestion in cell culture. the Buccione laboratory has been able to isolate invadopodia based on their triton-insoluble nature, and mass-spectrometry analysis will no doubt shed light on the nature of these controversial structures.
Friedl and colleagues have extended their initial observations to the intravital imaging of a melanoma xenograft model. in this system, a viewing chamber is placed on the stretched dorsal skin of a mouse and visualized using multiphoton microscopy. they were able to observe cells migrating collectively in a column through the extracellular matrix and along blood vessels. in a different approach, c. gaggioli from the E. Sahai laboratory (London, uK) used an organotypic culture system in which Sccs are plated on a collagen matrix seeded with caFs, and showed that the caFs are required for the invasion of the Sccs into the matrix. caFs are always present at the front of migrating chains of Sccs (Fig 2B) and act as leader cells, thereby promoting the migration of the cancer cells through the extracellular matrix (gaggioli et al, 2007) . therefore, in addition to supplying diffusible factors to promote tumour growth and angiogenesis, stromal fibroblasts have an active role in promoting invasion. D. deNardo, from the coussens laboratory (San Francisco, ca, uSa), revealed a further twist to the concept of leader cells. Following their interest in the interaction between tumours and the immune system, the members of the coussens laboratory have used mammosphere cultures to image these interactions. interestingly, macrophages can be observed at the leading edge of invasive strands of mammary cells, in much the same way as caFs can act as guides for carcinoma cells. can tumour cells therefore exploit the migratory abilities of the leukocytes that they recruit by secreting interleukins? these exciting findings highlight further the emerging role of stromal cells in the guidance of metastatic cells. the remarkable images from the Friedl and Sahai groups illustrate that leading cells and following cancer cells can remodel the matrix, creating corridors for other invasive cells (Fig 2B) . Does this matrix remodelling merely create Swiss cheese-like burrows that make the physical process of moving easier for other cancer cells? Do migrating caFs and metastatic cells leave behind a trail of landmarks-a process known as 'micropatterning' (Wolf et al, 2007) that can actively promote subsequent metastasis? the nature of these tracks, and whether they lead the tumour cells towards the blood vessels, can now be addressed using the organotypic and intravital models.
Therapy and metastasis
triggering an immune response against cancer cells by targeting tumour antigens has long been pursued as a therapeutic avenue for the treatment of cancer and is likely to remain topical due to the large number of tumour markers emerging from genomic studies. Monoclonal antibodies that recognize the adhesion molecule L1-caM and the long-studied metastasis driver Met are showing considerable promise as therapeutic agents, as illustrated by altevogt and by p. comoglio (candiolo, italy), respectively. in addition to potentiating an anti-tumour immune response by using exogenous monoclonal antibodies, certain therapeutic agents can trigger increased t-cell and natural killer-cell recruitment to the tumour site. B. Homey (Düsseldorf, germany) showed that skin tumours might evade the immune response by downregulating the expression of the keratinocyte-specific chemokine ccL27 in an EGFR/Ras-dependent manner (pivarcsi et al, 2007) . indeed, EGFR suppression by Erlotinib treatment in human patients frequently causes skin rash and induces elevated levels of ccL27 in the skin, whereas ccL27-neutralizing monoclonal antibodies increased tumour growth and metastasis in a syngeneic tumour mouse model. in many cases, it is difficult to diagnose a tumour before it becomes metastatic; therefore, treatments that prevent motility and entry into blood vessels will be ineffective, whereas the detection and destruction of micrometastases seems to be a promising treatment for many types of tumour (riethdorf et al, 2008) . K. pantel (Hamburg, germany) outlined the efforts of his group and the DiSMaL (Molecular Signatures as Diagnostic and therapeutic targets for Disseminated Epithelial Malignancies) European union consortium that he coordinates to tackle this issue. the pantel/DiSMaL team has established the detection of metastatic cells in both bone-marrow aspirates and blood. By using clinicaloutcome markers such as HEr2 they have been able to observe 
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reviews me e t ing rep or t HEr2-positive circulating tumour cells from patients with HEr2-negative primary tumours. therefore, tumours can accumulate new aberrations as they progress towards metastasis and a close monitoring of circulating tumour cells might allow physicians to adjust therapy to minimize metastasis. Many forms of cancer therapy can have devastating effects by indiscriminately killing healthy cells, as is the case for chemotherapy. However, M. Mareel (ghent, Belgium) suggested that radiotherapy can even promote metastasis, for example by stimulating the release of growth factors and cytokines, and by increasing the local proliferation and activation of stromal fibroblasts and macrophages (Madani et al, 2008) . Mareel therefore proposed that image-guided radiotherapy-in which computed tomography is used to guide radiotherapy only to the area where a tumour can be observedconcurrent with the administration of anti-metastasis drugs, might considerably reduce the chance of recurrence.
Cell biology/adhesion
the J. collard group (amsterdam, the Netherlands) has investigated the coupling of polarity regulators, such as the pKc-ζ-par3 complex, with cytoskeletal regulation in the context of cell migration. tiaM1, which is a guanine nucleotide-exchange factor responsible for activating the cytoskeletal regulator Rac, is also part of the pKc-ζ/par3 complex. as such, tiaM1 is required both for the establishment of mature tight junctions and for directional migration in motile cells (pegtel et al, 2007) . Ras-induced skin tumours and Pten -/-t lymphomas are dependent on tiaM, whereas Mycdriven mammary tumours are not, suggesting that the role of tiaM1 in tumorigenesis is context dependent.
S. Medjkane from the r. treisman laboratory (London, uK) showed that depletion of MrtF, which is an SrF co-factor, blocks tumour-cell migration both in cell culture and in an intravital mouse model, but does not affect tumour-cell proliferation. therefore, MrtF might couple cytoskeletal abnormalities with transcription of metastasis genes in tumour cells. the separable nature of the proliferative and invasive potentials was also explored by the g. Vande Woude laboratory (grand rapids, Mi, uSa). analysis of subclones of MEtresponsive glioblastoma cell lines revealed that HgF/MEt-induced MapK activation is associated with invasion, whereas Myc activation promotes the proliferative state. Vande Woude therefore suggested that genomic instability might drive tumour progression by selection of clones with either invasive or proliferative characteristics (gao et al, 2007) .
to understand metastasis, we need to establish the physical parameters-such as mechanical stress and adhesion-which the cells are subjected to at various stages of the process. J.p. thiery (Singapore) and his colleagues are using patch pipette-based force machines to measure cell-cell adhesion forces and cytoskeletal cortex association to plasma membranes. in particular, thiery showed that various cadherins-such as E-cadherin, N-cadherin and cdh7-mediate different adhesive forces. indeed, based on the cadherin type and the presence or absence of scaffolding components such as plakophilin 2, cell-cell contacts (adherens junctions) have different appearances by electron microscopy, as shown by S. rickelt from the W. Franke laboratory (Heidelberg, germany) . this probably reflects different physical adhesion characteristics, which might be associated with distinct steps in tumour progression. Further detailed studies on adherens junctions are likely not only to provide transformation markers but also to further our understanding of the different adhesive states associated with processes such as EMt, migration, intravasation and attachment to the secondary tumour site, all of which are crucially dependent on cell-cell contacts.
Conclusion
Overall, metastasis remains a puzzling and complex process. Many topics, such as the nature of stemness and metastatic driver genes, generated lively discussions, suggesting that much work remains to be done in these areas. Emerging fields, such as live imaging and functional genomics, gave us a glimpse of what the future might hold. the meeting was a great success and we hope that the organizers will host this exciting forum again in the future.
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